《China Phamaceuticals and Health Technologies Weekly (Aug. 12, 2010 – Aug. 18, 2010).pdf》由会员分享，可在线阅读，更多相关《China Phamaceuticals and Health Technologies Weekly (Aug. 12, 2010 – Aug. 18, 2010).pdf（27页珍藏版）》请在三一文库上搜索。
1、 Interfax China Pharmaceuticals docetaxel for injection and pemetrexed disodium for injection, both anti-tumor drugs; pa- lonosetron injection, a second generation 5-HT3 antagonist for treating chemotherapy-induced nausea and vomiting; and risperidone tablets, an anti-schizophrenia drug. Contact Inf
2、ormation Sector Pharmaceuticals Address No.243 Gongye Bei Road, Jinan, Shandong, China Telephone +86-0531-83127705, +86-0531-83127706, +86-0531-83127709, Facsimile +86-05531-83127700 Email webqilu- Website www.qilu- Source: www.qilu- 20 Interfax China Pharmaceuticals Beijing Tongrentang Co. Ltd. an
3、nual report 2009 Core businesses The company is mainly engaged in the manufacture and distribution of TCMs. Performance round-up Tongrentang achieved sales revenue of RMB 3.25 billion ($ 477.24 million) in 2009, up 10.59 percent from the previous year. Net profits grew 10.74 percent over the same pe
4、riod. The company received production approval for four drugs, including Shen Dan Huo Xue cap- sule which is used to treat cardiovascular diseases. The company also applied to conduct clinical trials of two new drugs. 21 Interfax China Pharmaceuticals and how mergers and acquisitions (M & A) and co
5、llaborations and alliances can help shorten R & D cycles, simplify operational proc- esses and drive business growth. Time: Sept. 16 Sept. 17 Location: Shanghai Marriott Hotel Changfeng Park Hosting Organization: China Decision Makers Consultancy (CDMC) Website: http:/www.ph- Contact: Judy Liu (Conf
6、erence Manager) Tel: +86 21 6840 7631 ext. 8015 Fax: +86 21 6840 7632 E-mail: PFC 25 Interfax China Pharmaceuticals & Health Technologies Weekly, Aug. 12, 2010 Aug. 18, 2010 25 WEEKLY MONITORS - CHINA WEEKLY MONITORS - China Keep up-to-date with breaking developments within your target industries i
7、n China with Inter- fax Chinas authoritative industry weeklies. China Investment Weekly China Pharmaceuticals & Health Technologies Weekly China Energy Weekly China TMT Weekly China Mining and Metals Weekly 26 Interfax China Pharmaceuticals & Health Technologies Weekly, Aug. 12, 2010 Aug. 18, 2010
8、26 INDUSTRY REPORTS - CHINA Industry-specific Reports Strengthen your China strategy through in-depth analysis and intelligence through special re- ports, tailored custom research, and periodic industry monitoring. China Carbon Trading Market up to 2012 Clean & Renewable Energy in China up to 2010 P
9、harmaceutical Outsourcing in China Looking Ahead Chinas Online and Mobile Gaming up to 2010 Chinas Aluminum Fabrication Industry up to 2010 China Commodities Report: Grains and Softs 2008 27 Interfax China Pharmaceuticals & Health Technologies Weekly, Aug. 12, 2010 Aug. 18, 2010 27 RESEARCH SERVICE
10、S Custom Research Sound China strategy is built upon sound insight. Fully understanding Chinas shifting terrain is an absolute prerequisite for success. Our team of business specialists focuses directly on your needs to conduct in-depth investigations to provide tailored intelligence and analysis. U
11、tilize our China expertise to ensure a solid foundation for your strategy in a wide variety of applications, including mergers and acquisitions, China entry, strategic business planning, new product launches and development, investment and funding analysis, due diligence and market intelligence, amo
12、ng others. Contact us Contact our research team for a full assessment of how we can use our accumulated China industry experience and unparalleled industry network to your full advantage. Email: Cynthia.wonginterfax- Phone: (852) 2537 2263 Fax: (852) 2537 2264 The information contained here is belie
13、ved to be fully reliable, but is provided for information purposes only with no warranty expressed or implied. The user shall fully indemnify and hold harmless Interfax Information Services B.V. and any of its Affiliates against any judgment, liability, loss, cost or damage resulting from or aris- ing out of the content the information and recommendations contained herein, as they are not to be used or considered as an offer to sell, or a solicitation of an offer to buy, or related to any omissions, delays, errors or inaccuracies. #